| Crystal structure of chimeric PDE5/PDE6 catalytic domain complexed with 3-isobutyl-1-methylxanthine… | |
Heteromer
P18545; P51160; | 537-859 | 100 | 1×ZN; 1×MG; 3×IBM; |
|
| Crystal structure of GAFb from the human phosphodiesterase 5 | | homo-4-mer | 346-509 | 100.0 | |
|
| crystal structure of unliganded PDE5A GAF domain | | homo-2-mer | 98-518 | 99.74 | |
|
| Crystal structure of PDE5A GAF domain (89-518) | | homo-2-mer | 101-518 | 99.73 | |
|
| Crystal structure of Human Phosphodiesterase 5 complexed with tadalafil(Cialis) | | homo-2-mer | 537-860 | 100.0 | 2×ZN; 2×MG; 2×CIA; |
|
| Catalytic Domain Of Human Phosphodiesterase 5A | | monomer | 534-862 | 100.0 | 1×ZN; 1×PO4; 1×CIT; |
|
| Crystal structure of PDE5A1 in complex with icarisid II | | monomer | 535-860 | 100 | 1×ZN; 1×MG; 1×7CA; |
|
| Crystal structure of the catalytic domain of unliganded PDE5 | | monomer | 535-860 | 100.0 | 1×ZN; 1×MG; |
|
| Crystal structure of PDE5 in complex with inhibitor 5R | | monomer | 535-860 | 100.0 | 1×SO4; 1×24E; 1×ZN; 1×MG; |
|
| Crystal structure of the PDE5A catalytic domain in complex with a novel inhibitor | | monomer | 535-860 | 100.0 | 1×ZN; 1×MG; 1×WAN; |
|
| Crystal structure of PDE5A1-IBMX | | monomer | 535-860 | 99.68 | 1×ZN; 1×MG; 1×IBM; |
|
| Crystal Structure of PDE5A1 catalytic domain in complex with Vardenafil | | monomer | 535-860 | 100.0 | 1×VDN; |
|
| Crystal structure of the PDE5A1 catalytic domain in complex with novel inhibitors | | monomer | 535-860 | 100.0 | 1×5EO; 1×ZN; 1×MG; |
|
| Crystal structure of PDE5 in complex with sildenafil | | monomer | 535-860 | 100 | 1×ZN; 1×MG; 1×VIA; |
|
| Crystal structure of PDE5 in complex with inhibitor LW1634 | | monomer | 535-860 | 100.0 | 1×ZN; 1×MG; 1×SO4; 1×9M0; |
|
| Crystal structure of PDE5 in complex with inhibitor LW1805 | | monomer | 535-860 | 100.0 | 1×SO4; 1×ZN; 1×MG; 1×9T9; |
|
| Catalytic Domain Of Human Phosphodiesterase 5A in Complex with Sildenafil | | monomer | 534-858 | 94.77 | 1×ZN; 1×MG; 1×VIA; 1×GOL; |
|
| Catalytic Domain Of Human Phosphodiesterase 5A In Complex With Tadalafil | | monomer | 534-858 | 94.77 | 1×ZN; 1×MG; 1×CIA; |
|
| Catalytic Domain Of Human Phosphodiesterase 5A In Complex With Vardenafil | | monomer | 534-858 | 94.77 | 1×ZN; 1×MG; 1×VDN; |
|
| Crystal structure of PDE5A in complex with CVT-313 | | monomer | 536-860 | 100.0 | 1×MG; 1×ZN; 1×AJR; |
|
| Catalytic Domain Of Human Phosphodiesterase 5A in Complex with GMP | | monomer | 534-858 | 94.77 | 1×ZN; 1×MG; 1×5GP; |
|
| Crystal structure of PDE5A in complex with a novel inhibitor | | monomer | 536-860 | 100.0 | 1×MG; 1×ZN; 1×B0C; |
|
| crystal structure of PDE5 in complex with a non-competitive inhibitor | | monomer | 535-859 | 100.0 | 1×FZA; |
|
| Crystal structure of the PDE5A1 catalytic domain in complex with novel inhibitors | | monomer | 536-860 | 100.0 | 1×5CO; 1×ZN; 5×MG; |
|
| Crystal structure of the PDE5A1 catalytic domain in complex with novel inhibitors | | monomer | 536-860 | 100.0 | 1×5FO; 1×ZN; 3×MG; |
|
| Human PDE5 catalytic core in complex with avanafil | | monomer | 536-859 | 100 | 1×E6L; 1×ZN; 1×MG; 1×SO4; |
|
| Crystal structure of the PDE5A1 catalytic domain in complex with novel inhibitors | | monomer | 535-858 | 100.0 | 1×5BA; 1×ZN; 1×MG; 2×PEG; |
|
| Crystal structure of the PDE5A1 catalytic domain in complex with novel inhibitors | | monomer | 535-858 | 100.0 | 1×5BB; 1×ZN; 1×MG; |
|
| Crystal structure of PDE5A in complex with a novel inhibitor | | monomer | 536-859 | 100.0 | 1×ZN; 1×MG; 1×VZF; |
|
| Crystal structure of Human Phosphodiesterase 5 complexed with Sildenafil(Viagra) | | monomer | 537-860 | 100.0 | 1×ZN; 1×MG; 1×VIA; |
|
| Crystal structure of PDE5A complexed with its inhibitor | | monomer | 535-858 | 100.0 | 1×PEG; 1×ZN; 1×MG; 1×NI5; |
|
| Crystal structure of the PDE5A1 catalytic domain in complex with novel inhibitors | | monomer | 537-860 | 100.0 | 1×ZN; 1×MG; 1×5IO; |
|
| Crystal structure of Human Phosphodiesterase 5 complexed with Vardenafil(Levitra) | | monomer | 537-860 | 100.0 | 1×ZN; 1×MG; 1×VDN; |
|
| Crystal structure of chimeric PDE5/PDE6 catalytic domain complexed with sildenafil | | monomer | 536-859 | 100 | 1×ZN; 1×MG; 1×VIA; |
|
| Investigation of Aminopyridiopyrazinones as PDE5 Inhibitors: Evaluation of Modifications to the Cen… | | monomer | 536-858 | 100 | 1×PD4; 1×ZN; 2×MG; |
|
| A novel series of potent and selective PDE5 inhibitor2 | | monomer | 536-858 | 95.52 | 1×ZN; 1×MG; 1×0H3; |
|
| Crystal structure of the PDE5A1 catalytic domain in complex with novel inhibitors | | monomer | 538-860 | 100.0 | 1×5BO; |
|
| A novel series of potent and selective PDE5 inhibitor1 | | monomer | 536-858 | 94.43 | 1×ZN; 1×MG; 1×TGE; |
|
| Crystal structure of PDE5A in complex with inhibitor L1 | | monomer | 537-859 | 100.0 | 1×ZN; 1×MG; 1×SO4; 1×2OI; |
|
| Rational Design of Highly Selective PDE5 inhibitors for the Treatment of Idiopathic Pulmonary Fibro… | | monomer | 537-859 | 100.0 | 1×WD3; 1×ZN; 1×MG; |
|
| Rational Design of Highly Selective PDE5 inhibitors for the Treatment of Idiopathic Pulmonary Fibro… | | monomer | 537-859 | 100.0 | 1×WDB; 1×ZN; 1×MG; |
|
| Crystal structure of PDE5A in complex with inhibitor L12 | | monomer | 537-859 | 100.0 | 1×ZN; 1×MG; 1×2VI; |
|
| Crystal structure of the catalytic domain of human PDE5A complexed with 2-(3-chlorobenzyl)-4-oxo-3,… | | monomer | 537-859 | 100.0 | 1×A1D5K; 1×ZN; 1×MG; |
|
| PDE5A for NaV1.7 | | monomer | 537-858 | 94.41 | 2×ZN; 1×6LK; |
|
| Crystal structure of N2 substituted pyrazolo pyrimidinones - a flipped binding mode in PDE5 | | monomer | 537-858 | 100 | 1×ZN; 1×MG; 1×3P4; 1×MES; |
|
| Identification, Synthesis, and SAR of Amino Substituted Pyrido[3,2b]pryaziones as Potent and Select… | | monomer | 537-858 | 100 | 1×PD6; 1×ZN; 1×MG; |
|
| Crystal structure of PDE5A in complex with its inhibitor | | monomer | 537-858 | 100.0 | 1×NI0; 1×MG; 1×PEG; 1×ZN; |
|